Calliditas Therapeutics Gets $1.1 Billion Takeover Bid From Asahi Kasei
Provided by
Dow Jones
By Dominic Chopping
STOCKHOLM--Swedish specialty pharmaceutical company Calliditas Therapeutics received a $1.1 billion takeover bid from Japan's Asahi Kasei.
The offer, of 208 Swedish kronor ($19.60) a share, represents a premium of 83% on the company's closing price on Monday, and the board unanimously recommended that shareholders accept the deal.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
May 28, 2024 03:17 ET (07:17 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations